Allogene Therapeutics, Inc. (ALLO)

I maintain a 'Buy' rating on Allogene Therapeutics, as their diverse allogeneic cell therapy pipeline shows encouraging early data and pivotal trials are progressing. ALLO's financial position remains solid, with over $300 million in liquidity, sufficient to reach key data catalysts through 2027 despite brisk cash burn. The upcoming ALPHA3 futility analysis in 1H 2026 is a critical catalyst; positive MRD data could significantly revalue the stock from current depressed levels.

ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer David D. Chang - Co-Founder, President, CEO & Director Geoffrey M.

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended June 30, 2025.

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the second quarter 2025 financial results and provide a business update on August 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it has selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen to be used in its ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL). This lymphodepletion regimen selection was made in conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee and following consultation with the U.S. Food and Drug Administration (FDA).

J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

Squarepoint Ops LLC cut its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 89.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,345 shares of the company’s stock after selling 168,152 shares during the period. Squarepoint Ops LLC’s holdings in Allogene Therapeutics were worth $43,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors also recently bought and sold shares of ALLO. Lynx1 Capital Management LP lifted its position in Allogene Therapeutics by 75.3% during the fourth quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company’s stock valued at $23,163,000 after acquiring an additional 4,672,349 shares during the last quarter. Foresite Capital Management VI LLC purchased a new stake in Allogene Therapeutics during the fourth quarter valued at approximately $7,345,000. Patient Square Capital LP purchased a new stake in Allogene Therapeutics during the fourth quarter valued at approximately $3,174,000. Gilead Sciences Inc. purchased a new stake in Allogene Therapeutics during the fourth quarter valued at approximately $2,464,000. Finally, Dimensional Fund Advisors LP lifted its position in Allogene Therapeutics by 30.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company’s stock valued at $7,586,000 after acquiring an additional 831,146 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock. Allogene Therapeutics Trading Up 3.5% NASDAQ ALLO opened at $1.46 on Wednesday. The company has a fifty day simple moving average of $1.34 and a two-hundred day simple moving average of $1.74. Allogene Therapeutics, Inc. has a 12-month low of $0.86 and a 12-month high of $3.78. The stock has a market cap of $319.35 million, a P/E ratio of -0.94 and a beta of 0.31. Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). As a group, sell-side analysts forecast that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current year. Insider Buying and Selling In related news, CEO David D. Chang sold 46,668 shares of the firm’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the completion of the transaction, the chief executive officer now owns 5,276,569 shares of the company’s stock, valued at $10,342,075.24. This trade represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 61,757 shares of company stock valued at $115,873 over the last 90 days. Insiders own 13.20% of the company’s stock. Wall Street Analysts Forecast Growth A number of equities research analysts recently commented on the stock. Citizens Jmp cut shares of Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 14th. Robert W. Baird decreased their target price on shares of Allogene Therapeutics from $12.00 to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, May 14th. Oppenheimer decreased their target price on shares of Allogene Therapeutics from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, May 14th. HC Wainwright decreased their price target on shares of Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, March 19th. Finally, Truist Financial decreased their price target on shares of Allogene Therapeutics from $14.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.44. Get Our Latest Research Report on ALLO Allogene Therapeutics Company Profile (Free Report) Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). See Also Five stocks we like better than Allogene Therapeutics What is a Microcap Stock? Everything You Need to Know AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What is Put Option Volume? Casey’s Surges on Strong Q4, More Gains Likely Ahead 3 Small Caps With Big Return Potential Government Mandate Sends eVTOL Stocks Flying

Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma (RCC) during an oral presentation at the 2025 ASCO Annual Meeting. The Phase 1 TRAVERSE trial enrolled patients with advanced or metastatic renal cell RCC. Leveraging the proprietary Dagger® technology to enable robust CAR T cell expansion, it stands as the first and only allogeneic CAR T product to show promise in treating solid tumors. The presentation focused on the Phase 1b expansion cohort from the Phase 1 TRAVERSE study in which patients were treated with a standard regimen of cyclophosphamide and fludarabine followed by a single dose of 80 million AlloCAR T™ cells.

Allogene's off-the-shelf CAR-T therapies offer scalable, rapid solutions with a diversified pipeline targeting hematologic malignancies, solid tumors, and autoimmune diseases. Upcoming ASCO data, especially for ALLO-316 in solid tumors, could be a major catalyst and validate Allogene's platform for broader indications. Despite immense upside potential, significant risks remain: safety, execution, regulatory uncertainty, and likely dilution due to future fundraising needs.

Allogene Therapeutics continues to advance its pipeline, with notable progress in key clinical trials and upcoming data readouts. The company's financial position remains stable, supported by a strong cash runway and prudent expense management. Key strengths include a differentiated allogeneic CAR-T platform and strategic partnerships, though clinical and regulatory risks remain significant.

SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four upcoming investor conferences in May and June.

SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of two abstracts on the American Society of Clinical Oncology (ASCO) website in advance of the 2025 ASCO Annual Meeting, taking place May 30-June 3 in Chicago, Illinois.

Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.